Status:
COMPLETED
A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)
Lead Sponsor:
Bayer
Conditions:
Myopic Choroidal Neovascularization
Eligibility:
All Genders
18+ years
Brief Summary
Being short sighted means that vision is blurry when looking at things far away. People with a condition called "pathologic myopia" are short sighted due to problems in the back layer of their eyes, a...
Eligibility Criteria
Inclusion
- Adult (Age ≥ 18 years) female or male patient.
- Anti-VEGF treatment naïve patients diagnosed with mCNV.
- Initiation of treatment with aflibercept was made as per investigator's routine treatment practice between 01 MAY 2017 and 31 AUG 2019.
Exclusion
- Any participation in an investigational program with interventions outside of routine clinical practice.
- Patients who have previously been treated with anti-VEGF intravitreal injections, systemic anti-VEGF or pro-VEGF treatments, as well as other intravitreal steroids or steroid implants for the study eye.
- Patients with another retinal disease (e.g. wet age-related macular degeneration,-wAMD; diabetic macular edema-DME; retinal vein occlusion-RVO), patients with advanced cataracts or glaucoma, or patients with scarring, fibrosis, or atrophy involving the center of the fovea.
Key Trial Info
Start Date :
June 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 11 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04524910
Start Date
June 16 2021
End Date
November 11 2022
Last Update
June 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Canada